Home › Funds › Ratan Capital Management LP › OCUL
Ratan Capital Management LP position in OCUL
OCULAR THERAPEUTIX INC · Health Care
Ratan Capital Management LP reported holding 70,792 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q2 2026 13F filing — a position valued at US$695K, representing 0.22% of its reported portfolio and ranking #36 among its reported holdings. Ratan Capital Management LP has disclosed OCUL holdings in 3 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Ratan Capital Management LP's OCUL position evolved
Ratan Capital Management LP first disclosed a stake in OCUL in Q1 2024 at 115,000 shares (US$1.0M). The position peaked in Q1 2026 at 188,775 shares, worth US$1.6M. Across 3 filings, Ratan Capital Management LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 70,792 shares valued at US$695K — a reduction of -117,983 shares quarter over quarter.. Notable position changes include a 62% trim in Q2 2026 (shares fell 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 115.00K | $1.05M | New |
| Q1 2026 | 188.78K | $1.60M | New |
| Q2 2026 | 70.79K | $695.18K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OCUL and 13F data
OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 43 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$193.3M), Avoro Capital Advisors LLC (US$123.1M), SUMMER ROAD LLC (US$119.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OCUL
- Deep Track Capital, LP 19.69M sh · $193.32M · Q2 2026
- Avoro Capital Advisors LLC 12.54M sh · $123.14M · Q2 2026
- SUMMER ROAD LLC 12.21M sh · $119.89M · Q2 2026
- Venrock Adviser, LLC 10.35M sh · $101.61M · Q2 2026
- Logos Global Management LP 5.30M sh · $52.05M · Q2 2026
- DELTEC ASSET MANAGEMENT LLC 2.48M sh · $24.32M · Q2 2026
- Octagon Capital Advisors LP 2.08M sh · $20.38M · Q2 2026
- TCG Crossover Management, LLC 1.65M sh · $16.18M · Q2 2026
- Defilade Capital Management, L.P. 1.49M sh · $14.63M · Q2 2026
- Boxer Capital Management, LLC 1.30M sh · $12.77M · Q2 2026
- Knoll Capital Management, LLC 1.15M sh · $11.30M · Q2 2026
More on Ratan Capital Management LP
FAQ
How long has Ratan Capital Management LP held OCUL?
Ratan Capital Management LP has disclosed OCUL holdings in 3 of the last 10 reported quarters, going back to Q1 2024.
What is Ratan Capital Management LP's current position in OCUL?
As of Q2 2026, Ratan Capital Management LP holds 70.79K shares of OCUL (OCULAR THERAPEUTIX INC), valued at $695.18K, representing 0.22% of its reported portfolio and ranking #36.
Has Ratan Capital Management LP been buying or selling OCUL?
In the latest 13F filing (Q2 2026), Ratan Capital Management LP reduced its position in OCUL. The position peaked in Q1 2026 at 188.78K shares.
Which other funds hold OCUL?
Other major institutional holders of OCUL include Deep Track Capital, LP, Avoro Capital Advisors LLC, SUMMER ROAD LLC, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.